StockNews.com started coverage on shares of Vanda Pharmaceuticals (NASDAQ:VNDA – Free Report) in a report released on Friday. The firm issued a hold rating on the biopharmaceutical company’s stock.

According to Vanda Research, the chip giant saw nearly $30 billion in inflows during the year. That handily beats out the SPDR S&P 500 ETF (SPY) and Tesla (TSLA). In the video above, Morning Brief ...

The result: The United Nations says that, at best, it will be able to raise enough money to help about 60% of the 307 million people it predicts will need humanitarian aid next year. That means at ...

Our team dishes on cowboycore, oversized trousers, Ellie the Elephant, the sickest fits they wore this year, and the hottest ...

The year 2024 has been a mixed ride for the biotech industry. It started on a positive note, attracting investors’ attention in areas with great commercial potential, like obesity, immunology and gene ...

(Reuters) - U.S. retail investor fund flows into Novo Nordisk (CSE: NOVOb) surged 32-fold on Friday, as the Danish ...

and do so, until that doesn't work anymore," said Marco Iachini, senior vice president of research at Vanda (VNDA). Shares of Novo Nordisk dropped 27% on Friday, erasing over $100 billion in ...